AP NEWS
ADVERTISEMENT
Press release content from PR Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from PR Newswire
Press release content from PR Newswire. The AP news staff was not involved in its creation.

Thermo Fisher Scientific Launches CE-IVD-Marked High Throughput COVID-19 Diagnostic Assay for Use On Its Automated Amplitude Platform

February 8, 2021 GMT

CARLSBAD, Calif., Feb. 8, 2021 /PRNewswire/ -- Thermo Fisher Scientific, the world leader in serving science, today launched its CE-IVD-Marked, Applied Biosystems TaqPath COVID–19 HT Kit that is compatible with the Amplitude platform. The high-throughput solution enables clinical and public health laboratories to efficiently test up to 8,000 COVID-19 samples a day with fewer staffing requirements and a reliable supply of kits, reagents and consumables.

The highly automated Amplitude platform is a molecular diagnostic system that allows labs to increase their COVID-19 testing capacity by combining Thermo Fisher’s extraction and real-time PCR instruments with liquid handling products from Tecan Group. The system leverages a high-throughput version of Thermo Fisher’s TaqPath COVID-19 CE-IVD RT-PCR Kit, which received CE-IVD Mark in March 2020.

ADVERTISEMENT

The high throughput diagnostic assay, compatible with the Amplitude platform, also received Interim Order Authorization from Health Canada on January 21. Thermo Fisher has secured a contract with a large provincial authority in Canada for Amplitude systems to help fight the pandemic.

“Accurate and reliable testing that can scale is essential in addressing the spread of any disease, especially COVID-19,” said Mark Smedley, president of the genetic sciences business of Thermo Fisher Scientific. “The Amplitude platform embodies our goal of empowering public health and clinical lab professionals to generate accurate results at higher volumes and use them to make informed health care decisions that lead to the management of a pandemic that is still raging around the world.”

With the Amplitude platform, customers receive a reliable supply agreement and up-front monthly delivery of reagents to ensure that COVID-19 testing needs are met. Thermo Fisher now has capacity to produce more than 20 million tests per week and continues to work closely with laboratories, governments, academic institutions and other stakeholders to ensure each has a reliable supply of tests and materials.

For more information on the Amplitude platform, please visit www.thermofisher.com/amplitude.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 80,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com.

ADVERTISEMENT

Media Contacts

Mauricio Minotta
Phone: +1 760-929-2456
E-mail: mauricio.minotta@thermofisher.com

Ariane Lovell
FINN Partners
Phone: +1 646 307 6317
E-mail: ariane.lovell@finnpartners.com

View original content: http://www.prnewswire.com/news-releases/thermo-fisher-scientific-launches-ce-ivd-marked-high-throughput-covid-19-diagnostic-assay-for-use-on-its-automated-amplitude-platform-301223475.html

SOURCE Thermo Fisher Scientific